Skip to main
PGEN

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen Inc. is projected to experience accelerated sales growth throughout 2026, bolstered by commercial momentum, the implementation of a permanent J-code for reimbursement effective April 1, and increased adoption among community physicians. Management has set optimistic expectations for 1Q26 product sales, forecasting over $18 million, which indicates a remarkable sequential growth of over five-fold compared to previous quarters. The company's robust pipeline of innovative therapies and advanced manufacturing capabilities via its proprietary technology platforms further contribute to a favorable long-term outlook for its stock.

Bears say

Precigen Inc reported fourth-quarter sales of $3.4 million, significantly below analysts' consensus estimate of $8.3 million. Additionally, the company incurred a net loss of $0.04 per diluted share, which, although better than the expected loss of $0.08 per share, indicates ongoing financial challenges. These disappointing sales figures, combined with net losses, suggest potential difficulties in achieving the expected revenue growth and profitability, contributing to a negative outlook for the stock.

Precigen (PGEN) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Buy based on their latest research and market trends.

According to 3 analysts, Precigen (PGEN) has a Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.